BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27899359)

  • 21. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Tyner JW; Gotlib J
    Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atypical CML: diagnosis and treatment.
    Breccia M
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation.
    Saqlain N; Ahmed N
    J Coll Physicians Surg Pak; 2016 Nov; 26(11):103-105. PubMed ID: 28666496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia.
    Sun Y; Wang Q; Zhang X; Zhang Z; Wang Q; Cen J; Zhu M; Pan J; Liu D; Wu D; Cai Y; Chen S
    Ann Hematol; 2023 Apr; 102(4):777-785. PubMed ID: 36735076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
    Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Masarova L; Naqvi K; Jabbour E; DiNardo CD; Takahashi K; Konopleva M; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Borthakur G; Estrov Z; Khoury JD; Loghavi S; Soltysiak KA; Pierce S; Bueso-Ramos C; Patel KP; Verstovsek S; Kantarjian HM; Bose P; Garcia-Manero G
    Cancer; 2021 Sep; 127(17):3113-3124. PubMed ID: 33914911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Transformation of secondary myelodysplastic syndrome to atypical chronic myeloid leukemia in a female patient with acute myeloid leukemia].
    Gritsaev SV; Kostroma II; Zapreev IM; Shmidt AV; Tiranova SA; Balashova VA; Martynkevich IS; Chubukina ZV; Semenova NY; Chechetkin AV
    Ter Arkh; 2016; 88(7):104-108. PubMed ID: 27459623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
    Fend F; Horn T; Koch I; Vela T; Orazi A
    Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
    Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
    Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical chronic myeloid leukaemia with trisomy 13: a case report.
    Guo-yu H; Chao-hui Y; Kui T; Zhen-zhen C
    Chin Med Sci J; 2011 Dec; 26(4):254-6. PubMed ID: 22218057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's different about atypical CML and chronic neutrophilic leukemia?
    Dao KH; Tyner JW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.
    Rocca S; Carrà G; Poggio P; Morotti A; Brancaccio M
    Mol Cancer; 2018 Feb; 17(1):40. PubMed ID: 29455651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of single-agent decitabine in atypical chronic myeloid leukemia.
    Hausmann H; Bhatt VR; Yuan J; Maness LJ; Ganti AK
    J Oncol Pharm Pract; 2016 Dec; 22(6):790-794. PubMed ID: 26378157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solving the Puzzle: The Diagnosis of Atypical Chronic Myeloid Leukemia, BCR-ABL1-Negative (aCML).
    Danyal K; Devitt K; Gardner JA
    J Assoc Genet Technol; 2021; 47(3):127-131. PubMed ID: 34491231
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Iaquinta G; Scalzulli E; Angeloni S; Carmosino I; Costa A; Ielo C; Passucci M; Masucci C; Martelli M; Grammatico P; Breccia M
    Leuk Lymphoma; 2023 Oct; 64(10):1730-1732. PubMed ID: 37435984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.